INanoBio Inc.
INanoBio is dedicated to developing high-accuracy early disease diagnostics through innovative nano-biotechnology platforms and machine learning. Their mission is to enable preemptive medicine by detecting diseases at pre-symptomatic stages, thus improving therapeutic outcomes and personalizing treatment. They focus on genome sequencing and cancer diagnostics, aiming to make genome sequencing faster and more affordable, and to create blood tests for early cancer detection without biopsies.
Industries
Nr. of Employees
small (1-50)
INanoBio Inc.
Patents
Field effect transistor, device including the transistor, and methods of forming and using same
US-12007389-B2
View DetailsNanopore sensor, structure and device including the sensor, and methods of forming and using same
US-11977069-B2
View DetailsField effect transistor, device including the transistor, and methods of forming and using same
US-9341592-B2
View Details
Field effect transistor, device including the transistor, and methods of forming and using same
US-12007389-B2
View DetailsNanopore sensor, structure and device including the sensor, and methods of forming and using same
US-11977069-B2
View DetailsField effect transistor, device including the transistor, and methods of forming and using same
US-9341592-B2
View DetailsProducts
Ultra-fast whole-genome sequencer (development-stage)
A sequencing platform under development based on CMOS 3D nanopore-transistor sensors intended for rapid, low-cost whole-human-genome sequencing.
Blood-based cancer detection assays (development-stage)
Assay development programs aiming to detect cancer-specific molecular biomarkers in blood at pre-symptomatic stages to enable early intervention and reduce the need for tissue biopsy.
Automated high-throughput proteomic assay system (development-stage)
An automated system for performing high-throughput proteomic assays developed under NIH SBIR funding to scale proteomic measurements.
Ultra-fast whole-genome sequencer (development-stage)
A sequencing platform under development based on CMOS 3D nanopore-transistor sensors intended for rapid, low-cost whole-human-genome sequencing.
Blood-based cancer detection assays (development-stage)
Assay development programs aiming to detect cancer-specific molecular biomarkers in blood at pre-symptomatic stages to enable early intervention and reduce the need for tissue biopsy.
Automated high-throughput proteomic assay system (development-stage)
An automated system for performing high-throughput proteomic assays developed under NIH SBIR funding to scale proteomic measurements.
Services
Joint development and translation of diagnostic assays and sensing platforms with clinical and research partners, including clinical validation collaborations for CNS diagnostics.
Systems-biology and machine-learning driven analysis to identify disease-specific molecular signatures from multi-omic or proteomic data for early-detection assay development.
Joint development and translation of diagnostic assays and sensing platforms with clinical and research partners, including clinical validation collaborations for CNS diagnostics.
Systems-biology and machine-learning driven analysis to identify disease-specific molecular signatures from multi-omic or proteomic data for early-detection assay development.
Expertise Areas
- Whole-genome sequencing platform development
- Nanopore-based sensor design
- Epigenetic sequencing
- Blood-based cancer diagnostics and biomarker discovery
Key Technologies
- Nanopore-transistor sequencing sensors
- CMOS-based semiconductor sensor fabrication
- Epigenetic sequencing methods
- High-sensitivity blood-based molecular assays
News & Updates
INanoBio CEO, Bharath Takulapalli will be presenting at the Precision Medicine World Conference 2022 at the Santa Clara Convention Center.
INanoBio CEO, Bharath Takulapalli to speak at the MEMS & Sensors Technical Congress at the David Brower Center in Berkeley.
Nanopore Sequencing Firm INanoBio announces the development of a fast sensor for ultra-fast DNA sequencing.
INanoBio received up to $5.4 million from DARPA for developing a silicon nanapore sequencer.
Dr. Abhay Sanan and JP Millon join INanoBio's Board of Directors as part of 2018 Series Seed financing.
INanoBio awarded $0.7 million by NIH to develop an automated high throughput proteomic system.
INanoBio CEO, Bharath Takulapalli will be presenting at the Precision Medicine World Conference 2022 at the Santa Clara Convention Center.
INanoBio CEO, Bharath Takulapalli to speak at the MEMS & Sensors Technical Congress at the David Brower Center in Berkeley.
Nanopore Sequencing Firm INanoBio announces the development of a fast sensor for ultra-fast DNA sequencing.
INanoBio received up to $5.4 million from DARPA for developing a silicon nanapore sequencer.
Dr. Abhay Sanan and JP Millon join INanoBio's Board of Directors as part of 2018 Series Seed financing.
INanoBio awarded $0.7 million by NIH to develop an automated high throughput proteomic system.